Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

10.63
-0.4900-4.41%
Pre-market: 10.690.0600+0.56%07:06 EDT
Volume:4.50M
Turnover:47.88M
Market Cap:2.74B
PE:3.19
High:11.10
Open:11.04
Low:10.45
Close:11.12
Loading ...

BRIEF-Update On FDA Review Of VTAMA Cream 1% For Atopic Dermatitis In Adults And Children Aged 2 And Older

Reuters
·
05 Nov 2024

Organon & Co - FDA Raises No Safety or Efficacy Concerns for Vtama

THOMSON REUTERS
·
05 Nov 2024

Organon & Co - New Target Date for Vtama Review Is March 12, 2025

THOMSON REUTERS
·
05 Nov 2024

Update on FDA Review of Vtama® (Tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

THOMSON REUTERS
·
05 Nov 2024

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Simply Wall St.
·
01 Nov 2024

Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL), Organon (OGN) and Haleon PLC Sponsored ADR (HLN)

TIPRANKS
·
01 Nov 2024

Organon & Co. : Morgan Stanley Cuts Target Price to $17.00 From $18.00

THOMSON REUTERS
·
01 Nov 2024

Piper Sandler Reaffirms Their Buy Rating on Organon (OGN)

TIPRANKS
·
01 Nov 2024

Organon & Co reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

Stock Track | Organon Shares Rally on Q3 Revenue Beat and Upbeat Outlook

Stock Track
·
31 Oct 2024

Organon Shares Rise After Q3 Revenue Beat

MT Newswires Live
·
31 Oct 2024

Organon declares $0.28 dividend

seekingalpha
·
31 Oct 2024

BRIEF-Organon Reports Results For The Third Quarter Ended Sept. 30, 2024

Reuters
·
31 Oct 2024

Organon Expects 2024 Adjusted EBITDA Margin Of 30%-31% Compared To Prior Guidance Of 31%-33%

Benzinga
·
31 Oct 2024

Organon Expects 2024 Revenues Of $6.375B-$6.425B Versus Prior Guidance Of $6.25B-$6.45B And Consensus Of $6.382B

Benzinga
·
31 Oct 2024

Organon Q3 2024 Adj EPS $0.87 Misses $0.90 Estimate, Sales $1.58B Beat $1.56B Estimate

Benzinga
·
31 Oct 2024

Organon Q3 Adjusted Ebitda Margin 29%

THOMSON REUTERS
·
31 Oct 2024

Organon Q3 Adjusted EPS USD 0.87 VS. Ibes Estimate USD 0.9

THOMSON REUTERS
·
31 Oct 2024

Organon & Co: Guidance Range for Full Year 2024 Revenue Narrowed to $6.375 Bln to $6.425 Bln

THOMSON REUTERS
·
31 Oct 2024

Organon Says US FDA Accepts Biologic License Application for Proposed Denosumab Biosimilar HLX14

MT Newswires Live
·
30 Oct 2024